UCB Media Room: General Meeting of Shareholders 2022


https://mb.cision.com/Public/18595/3556109/88d04748d2757e1a_800x800ar.png ** UCB=E2=80=99s General Meeting of Shareholders 2022 —————– ———————————————— =C2 =B7 For the 2021 financial year: Gross dividend of =E2=82=AC 1.30 per share = (+ 2.36%), payable on May 3, 2022 =C2=B7 All agenda items submitted vote approved =C2=B7 Message from Jean-Christophe Tellier, CEO of UCB is available on the company’s global website U= CB=E2=80=99 Brussels (Belgium), 28 April 2022 =E2= 80=93 18:00 (CEST) (regulated information) =E2=80=93 Today, UCB held its Annual General Meeting of Shareholders = (AGA) and an Extraordinary General Meeting (AGE). The company offered UCB shareholders the choice of participating in person or voting by proxy and following the meeting online. At the AGM 147,925 5= 50 shares (77.83% of the shares with voting rights) were represented.=C2=A0 The message from Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB,= published at the occasion of this general meeting, is available on the UCB= website (https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeti= ng-2022) . During his remarks, Mr. Tellier commented: =E2=80=9C2021 has been a very good year, and 2022 is shaping up to be a key transition year =E2=80=A6 Our continued strong financial performance coupled with results impressive clinical milestone= achievements and strategic partnerships have provided us with the building blocks we need to lead us to our 2025 guidance.=E2=80=9D=C2=A0 Jean-Christophe Tellier also added: =E2= 80=9CLooking at UCB today, we have built a solid foundation, allowing us to focus on executing our strategy in the years to come. We are therefore confident that we can live up to our ambition and commitment to deliver value to patients now and in the future.=E2=80==9D The AGM approved the payment of a dividend for the financial year 2021 gross o= f =E2= 82=AC 1.30 per share (net dividend of =E2=82=AC 0.91 per share) to be compared to =E2=82=AC 1.27 per share for 2020 (net = E2=82=AC 0.889). The detachment date is April 29, 2022, the dividend (coupon no. 25) will be paid from May 3, 2022. During the AGM, several renewals of members of the composition of the Board were approved. The General Meeting renewed the mandates of Mrs. Kay Davies as independent director for a period of 4 years and of Mr. Jean-Christophe Tellier and Mr. C=C3=A9= dric Rijckevorsel as directors for a period of Four years. Ms. Kay Davies chairs the Scientific Committee of the Board of Directors and provides unique scientific input at the Board level. For CVs of Board members, please visit UCB’s website: https://www.ucb.com/investors/UCB-governance.=C2=A0 All other agenda items submitted to the vote of the AGM and the EGM have been approved = by the shareholders. More information, including voting details, will soon be available on the company’s website (https://www.ucb.com/investors/UC=B-shareholders/Shareholders-meeting-2022). UCB’s 2021 Integrated Annual Report can be downloaded from UCB’s website at https://www.ucb.com/investors/Download-center or is available on the online portal at https ://reports.ucb.com/ . The financial results for the first half of 2022 will be published on July 28, 2022.=C2=A0 Next year’s General Meeting will be held on April 27, 2023. For more information, contact UCB:=C2=A0 Investor Relations Antje Witte Investor Relations, UCB T +32.2.559.9414 [email protected]=C2=A0 Global Communications=C2=A0 Laurent Schots Media Relations, UCB T+32.2.559.9264 [email protected] =C2=A0 About UCB= C2=A0 UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with diseases severe imm= a or central nervous system. With approximately 8,600 people in almost 40 countries, the company generated a turnover of =E2=82=AC 5.8 billion= llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us = on Twitter: @UCB_news Forward-Looking Statements=C2=A0 This press release may contain forward-looking statements, including, without limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, = = E2=80=9It is planned=E2=80=9D, =E2=80=9It is planned=E2=80=9D, =E2=80=9It is planned= =E2=80=9D, = E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=ates=E2=80=9D, =E2=80=9Cmay=E2=80 =9D, =E2=80=9Cwill= E2=80=9D, =E2=80=9Ccont= inue=E2=80=9D and similar expressions. These forward-looking statements are based on management’s current plans, estimates and beliefs. All statements, other than statements of historical fact, are statements that could be deemed to be forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other information financial information, expected legal information, arbitration, political, regulatory or clinical results or practices and other similar estimates and results. By their nature, these forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that could cause the actual results, financial condition, performance or achievements of UCB, = or industry results, to differ materially from those that may be expressed=or implied by such forward-looking statements contained in this press release=se. Important factors that could cause such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain or obtain necessary regulatory approvals at acceptable or timely terms, costs associated with research and development, changes in the outlook for products in development or under development by UCB, effects of future court rulings or government investigations, safety, quality, integrity manufacturing data or issues; potential or actual data security and privacy breaches or disruptions to our information technology systems, product liability claims, challenges to patent protection of products or product candidates, competition from other products, including biosimilars, changes in laws or regulations, currency exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and the hiring and retaining its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval, or that new indications for existing products will be developed and approved. The transition from concept to commercial product is uncertain; preclinical results do not guarantee the safety and efficacy of product candidates in humans. Until now, the complexity of the human body cannot be replicated in computer models, cell culture systems, or animal models. The length of time to complete clinical trials and obtain regulatory approval for marketing products has varied in the past and UCB expects similar unpredictability in the future. Products or potential products that are the subject of partnerships, joint ventures or licensing collaborations may be the subject of disputes between the partners or may prove less safe, effective = or commercially successful than UCB might have believe in the origin. beginning of such a partnership. UCB=E2=80=99’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB might have believed at the time of acquisition. In addition, UCB or others may discover safety issues, side effects or manufacturing issues with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of the products in UCB=E2=80=99 that involve an entire class of products may have a material adverse effect on sales of the entire class of affected products. Additionally, sales may be impacted by international and domestic trends toward managed care and cost containment in healthcare, including pricing pressure, political and public scrutiny, customer patterns or practices. and prescribers, and reimbursement policies imposed by third-party payers as well as legislation affecting biop= pharmaceutical pricing and reimbursement activities and results. Finally, an outage, cyberattack or breach of information security could compromise the confidentiality, integrity and availability of UCB’s data and systems=E2=80=99.=C2=A0 Given these uncertainties , you should not place undue reliance on such forward-looking statements. There can be no guarantee that the investigational or approved products potentially described in this press release will be submitted or approved for sale or for any additional indication or labeling in any particular market or time, and there can be no there being no guarantee that these products will be or will continue to be commercially successful in the future. UCB provides this information, including forward-looking statements, only as of the date of this press release and does not reflect any potential impact of the evolution of the COVID-19 pandemic, unless otherwise stated. = UCB is diligently monitoring global developments to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any obligation = to update any information contained in this press release, either to confirm actual results or to report or reflect any change in its forward-looking statements in this regard or any change in events, conditions or c= circumstances on which such statement is based, unless such statement is = required under applicable laws and regulations. /903c5e997866= cd9a.pdf) GenericFile UCB AGM 2022 PR ENG (https://mb.cision.com/Public/18595/3556109/bd1c5438d85= 9a0ff.pdf) GenericFile UCB AGM 2022 PR FR (https://mb.cision .com/Public/18595/3556109/89561356290b=e782.pdf) ______________________ If you prefer not to receive future communications from UCB SA, please click on https://eu.vocuspr.com/OptOut.aspx?2973226x20421x103694x1x6868579x2400=0x6&Email =3Dregnews%40symexglobal.com. UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B-1070 Belgium
Previous Nicolas Pepe can end an ongoing trend at Arsenal if he completes a £25m summer transfer
Next Boris Becker faces jail after guilty verdicts